Chemotherapy-induced peripheral neuropathy in the detroit research on cancer survivors (ROCS) cohort.

ABSTRACT:

Purpose

Improved life expectancy has increased the likelihood for long-term complications from chemotherapy among cancer survivors. One burdensome complication is chemotherapy-induced peripheral neuropathy (CIPN). We evaluated rates of CIPN outcomes in the Detroit Research on Cancer Survivorship (ROCS) cohort.

Methods

The population included 1,034 African American (AA) survivors who received chemotherapy for breast, colorectal, lung or prostate cancer. CIPN prevalence was based on initial occurrence of worsening of self-reported pain, numbness or tingling after chemotherapy. Current CIPN included symptoms still present at the time of the survey, and persistent CIPN symptoms were present 12 or more months post-chemotherapy. CIPN severity was ranked as mild, moderate or severe

SUBMITTER: Sreeram K 

PROVIDER: S-EPMC10373434 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature